for people ages 30 years and up (full criteria)
at UC Davis UCLA
study started
estimated completion
Principal Investigator
by John Belperio, MD (ucla)Justin Oldham, MD (ucdavis)



This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.

Official Title

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype Prospective Outcomes (IPF-PRO/ILD-PRO) Registry


Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease Idiopathic pulmonary fibrosis Pulmonary fibrosis IPF Registry 1199.174 Interstitial Lung Disease ILD Interstitial Lung Disease with Progressive Phenotype Lung Diseases Lung Diseases, Interstitial Fibrosis


You can join if…

Open to people ages 30 years and up

  • Willing and able to provide informed consent
  • Established a new diagnosis of IPF by the enrolling subspecialty center (as defined by ATS/ERS/JRS/ALAT criteria)
  • Age 30 years or older, or
  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial, Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

You CAN'T join if...

  • Malignancy, treated or untreated, other than skin or early stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in a clinical trial at the time of enrollment in this registry


  • University of California - Los Angeles accepting new patients
    Los Angeles California 90024 United States
  • University of California, Davis accepting new patients
    Sacramento California 95817 United States

Lead Scientists at University of California Health

  • John Belperio, MD (ucla)
    Professor, Medicine. Authored (or co-authored) 154 research publications.
  • Justin Oldham, MD (ucdavis)
    Assistant Professor, Pulmonary, Critical Care, and Sleep Medicine. Authored (or co-authored) 79 research publications.


accepting new patients
Start Date
Completion Date
Duke University
Study Type
Observational [Patient Registry]
Last Updated